en.wikipedia.org/wiki/Juno_Therapeutics

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of ... In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate ...

www.geekwire.com/2018/juno-therapeutics-agrees-pay-24m-stockholders-suit-disclosure-patient-deaths

Sep 4, 2018 ... As part of the settlement, anyone who acquired Juno stock between June 4, 2016 and Nov. ... admission of wrongdoing on the part of Juno or the executives named in the lawsuit, including Bishop, Juno's current chief medical ...

www.fool.com/investing/2018/01/02/why-2017-was-a-year-to-remember-for-juno-therapeut.aspx

Jan 2, 2018 ... After a rough 2016 in which Juno Therapeutics' (NASDAQ:JUNO) lead ... What company would want to buy Juno, only to have to split profits on ...

www.fool.com/investing/2016/06/26/better-buy-bellicum-pharmaceuticals-inc-vs-juno-th.aspx

Jun 26, 2016 ... Could the less-heralded Bellicum be the smarter pick for investors than rising star Juno Therapeutics?

ir.junotherapeutics.com/news-releases/news-release-details/juno-therapeutics-signs-licensing-agreements-lilly-oncotracker

Dec 6, 2017 ... 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), ... For more information visit www.fredhutch.org or follow Fred Hutch on Facebook , Twitter or ... OncoTracker, Inc. (“OncoTracker”) is a Los Angeles -based medical ...

www.reuters.com/finance/stocks/overview/JUNO.O

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer.

www.junotherapeutics.com/about-us/our-values

We're on a quest to radically change the course of medicine by aligning our investments in research, manufacturing & people to change the way we treat ...

www.marketscreener.com/JUNO-THERAPEUTICS-INC-19157251

Juno Therapeutics Inc (NASDAQ:JUNO) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share Juno Therapeutics Inc ... Biotechnology & Medical Research ... Completion of Acquisition or Disposition of Assets, No.

www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153

Jan 22, 2018 ... Celgene Corp. CELG 1.65% on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that ...